Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC

Major Inclusion Criteria:

1. Male or female, 18 years of age or older

2. ECOG performance status of 0 or 1

3. Histologically or cytologically confirmed SCLC

4. Have at least 1 lesion that meets the criteria for being measurable, as defined byRECIST 1.1

5. Have a life expectancy of at least 3 months

Major Exclusion Criteria:

1. Serious, non-healing wound, ulcer or bone fracture

2. Major surgical procedure within 28 days or minor surgical procedure performed within 7 days prior to treatment

3. Active bleeding or pathologic conditions that carry high risk of bleeding, such asknown bleeding disorder, coagulopathy, or tumor involving major vessels

4. Clinically significant cardiovascular disease including uncontrolled hypertension;myocardial infarction or unstable angina within 6 months prior to enrollment; NewYork Heart Association (NYHA) Grade II or greater congestive heart failure seriouscardiac arrhythmia requiring medication; and Grade II or greater peripheral vasculardisease

5. Hemoptysis within 3 months prior to enrollment

6. Concomitant treatment with strong inhibitors or inducers of CYP3A4, CYP2C9 andCYP2C19 within 14 days prior to enrollment and during the study unless there is anemergent or life-threatening medical condition that required it.

More information available upon request